Cd123-specific chimeric antigen receptor redirected t cells and methods of their use

A technology of chimeric antigen receptors and cells, applied in the direction of receptors/cell surface antigens/cell surface determinants, antibodies, animal cells, etc., can solve problems such as recurrence

Active Publication Date: 2016-03-09
CITY OF HOPE
View PDF4 Cites 17 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Although current treatment regimens for AML achieve complete responses in selected patients, many eventually relapse, highlighting the need for new treatments that can elicit more durable responses

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cd123-specific chimeric antigen receptor redirected t cells and methods of their use
  • Cd123-specific chimeric antigen receptor redirected t cells and methods of their use
  • Cd123-specific chimeric antigen receptor redirected t cells and methods of their use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0104] Example 1: T cells transduced with CD123CAR exhibit potent cytolytic activity and multiple effector functions against AML in vitro

[0105] Materials and methods

[0106] Cell lines. Unless otherwise stated, all cell lines were maintained in RPMI 1640 (Irvine Scientific) supplemented with 2 mM L-glutamine, 25 mM HEPES, and 10% heat-inactivated FCS (Hyclone) (hereinafter referred to as complete medium (CM)). Peripheral blood mononuclear cells (PBMC) were transformed with Epstein-Barr virus to generate lymphoblastoid cell lines (LCL) as previously described [19]. LCL-OKT3 cells express membrane-bound OKT3 and were grown in CM supplemented with 0.4 mg / ml hygromycin [20]. K562 cells were obtained from ATCC and cultured as recommended. KG1a cells (kindly provided by Dr. Ravi Bhatia) were maintained in IMDM (Irvine Scientific) supplemented with 25 mM HEPES, 4 mM L-glutamine (Irvine Scientific) and 20% FCS. 293T cells (a kind gift from the Center for Biomedicine and Genetic...

Embodiment 2

[0149] Example 2: T cells transduced with CD123CAR delay leukemia progression in vivo

[0150] CD123CAR constructs. The 26292CAR (S228P+L235E) and 32716CAR (S228P+L235E) constructs were generated as described in Example 1 above. Two additional CD123CAR constructs containing an additional mutation (N297Q) at position 297 in the IgG4 hinge for each scFv (“26292CAR(S228P+L235E+N297Q)” and “32716CAR(S228P+L235E+N297Q)” were also generated N297Q)")( Figure 12 and 13 , mutate bold and underline).

[0151] NSG mice were transplanted with AML tumor cells (day 0) and treated with 5.0x10 6 CAR+ T cells were processed and leukemia progression was monitored by bioluminescent imaging. Such as Figure 8 Shown in , the leukemic burden progressed at day 8 compared to the treatment day for mice treated with T cells transduced with 26292CAR(S228P+L235E), indicative of the use of the CD123CAR construct with hinge region mutations at positions S228P and L235E Transduced cells have no effec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A family of chimeric antigen receptors (CARs) containing a CD123 specific scFv was developed to target different epitopes on CD123. In some embodiments, such a CD123 chimeric antigen receptor (CD123CAR) gene includes an anti-CD123 scFv region fused in frame to a modified IgG4 hinge region comprising an S228P substitution, an L235E substitution, and optionally an N297Q substitution; a costimulatory signaling domain; and a T cell receptor (TCR) zeta chain signaling domain. When expressed in healthy donor T cells (CD4 / CD8), the CD123CARs redirect T cell specificity and mediated potent effector activity against CD123+ cell lines as well as primary AML patient samples. Further, T cells obtained from patients with active AML can be modified to express CD123CAR genes and are able to lyse autologous AML blasts in vitro. Finally, a single dose of 5.0 x 106 CAR123 T cells results in significantly delayed leukemic progression in mice. These results suggest that CD123CAR-transduced T cells may be used as an immunotherapy for the treatment of high risk AML.

Description

[0001] priority claim [0002] This application claims priority to US Patent Application Serial No. 13 / 844,048, filed March 15, 2013, which is incorporated by reference in its entirety, including the drawings. [0003] government interest [0004] This invention was made with Government support under NIH grants P50CA107399, P01CA030206, and M01RR0004. The government has certain rights in this invention. Background of the invention [0005] Acute myeloid leukemia (AML) is characterized by rapid proliferation of immature myeloid cells in the bone marrow, resulting in dysfunctional hematopoiesis [1]. First-line treatment of acute myeloid leukemia (AML) has remained essentially unchanged for almost 50 years, and AML remains a disease with a poor prognosis. Although standard induction induces complete remission, many patients eventually relapse and succumb to the disease [2]. Therefore, the development of new treatments for AML is of paramount importance. [0006] Allogeneic h...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/62C12N5/10A61K48/00A61K39/00A61P35/02
CPCA61K2039/505C07K2317/622C07K2319/00C07K14/7051A61K35/17C07K16/2866A61P35/00A61P35/02A61P43/00C12N15/85C12N5/0636C12N2510/00C07K2317/53C07K2317/24C07K2319/02C07K2319/03
Inventor S.福曼A.马迪罗斯
Owner CITY OF HOPE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap